These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

260 related articles for article (PubMed ID: 36700211)

  • 21. A Comprehensive Biomarker Analysis of Microsatellite Unstable/Mismatch Repair Deficient Colorectal Cancer Cohort Treated with Immunotherapy.
    Élez E; Mulet-Margalef N; Sanso M; Ruiz-Pace F; Mancuso FM; Comas R; Ros J; Argilés G; Martini G; Sanz-Garcia E; Baraibar I; Salvà F; Noguerido A; Cuadra-Urteaga JL; Fasani R; Garcia A; Jimenez J; Aguilar S; Landolfi S; Hernández-Losa J; Braña I; Nuciforo P; Dienstmann R; Tabernero J; Salazar R; Vivancos A
    Int J Mol Sci; 2022 Dec; 24(1):. PubMed ID: 36613564
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Clinicopathological features of sporadic MSI colorectal cancer and Lynch syndrome: a single-center retrospective cohort study.
    Nakayama Y; Iijima T; Inokuchi T; Kojika E; Takao M; Takao A; Koizumi K; Horiguchi SI; Hishima T; Yamaguchi T
    Int J Clin Oncol; 2021 Oct; 26(10):1881-1889. PubMed ID: 34148153
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Multilevel genomics of colorectal cancers with microsatellite instability-clinical impact of JAK1 mutations and consensus molecular subtype 1.
    Sveen A; Johannessen B; Tengs T; Danielsen SA; Eilertsen IA; Lind GE; Berg KCG; Leithe E; Meza-Zepeda LA; Domingo E; Myklebost O; Kerr D; Tomlinson I; Nesbakken A; Skotheim RI; Lothe RA
    Genome Med; 2017 May; 9(1):46. PubMed ID: 28539123
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Is There a Role for Programmed Death Ligand-1 Testing and Immunotherapy in Colorectal Cancer With Microsatellite Instability? Part I-Colorectal Cancer: Microsatellite Instability, Testing, and Clinical Implications.
    Marginean EC; Melosky B
    Arch Pathol Lab Med; 2018 Jan; 142(1):17-25. PubMed ID: 29144791
    [TBL] [Abstract][Full Text] [Related]  

  • 25. PTCH1 mutation promotes antitumor immunity and the response to immune checkpoint inhibitors in colorectal cancer patients.
    Wang Y; Chen H; Jiao X; Wu L; Yang Y; Zhang J; Wu L; Liu C; Zhuo N; Li S; Gong J; Li J; Zhang X; Wang X; Peng Z; Qi C; Wang Z; Li J; Li Y; Lu Z; Zhang H; Shen L
    Cancer Immunol Immunother; 2022 Jan; 71(1):111-120. PubMed ID: 34028566
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Neoadjuvant Immunotherapy for MSI-H/dMMR Locally Advanced Colorectal Cancer: New Strategies and Unveiled Opportunities.
    Zhang X; Wu T; Cai X; Dong J; Xia C; Zhou Y; Ding R; Yang R; Tan J; Zhang L; Zhang Y; Wang Y; Dong C; Li Y
    Front Immunol; 2022; 13():795972. PubMed ID: 35371084
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Opportunities for immunotherapy in microsatellite instable colorectal cancer.
    Westdorp H; Fennemann FL; Weren RD; Bisseling TM; Ligtenberg MJ; Figdor CG; Schreibelt G; Hoogerbrugge N; Wimmers F; de Vries IJ
    Cancer Immunol Immunother; 2016 Oct; 65(10):1249-59. PubMed ID: 27060000
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The Evolving Role of Consensus Molecular Subtypes: a Step Beyond Inpatient Selection for Treatment of Colorectal Cancer.
    Ros J; Baraibar I; Martini G; Salvà F; Saoudi N; Cuadra-Urteaga JL; Dienstmann R; Tabernero J; Élez E
    Curr Treat Options Oncol; 2021 Nov; 22(12):113. PubMed ID: 34741675
    [TBL] [Abstract][Full Text] [Related]  

  • 29. T cell-inflamed gene expression profile is associated with favorable disease-specific survival in non-hypermutated microsatellite-stable colorectal cancer patients.
    Yin H; Harrison TA; Thomas SS; Sather CL; Koehne AL; Malen RC; Reedy AM; Wurscher MA; Hsu L; Phipps AI; Zaidi SHE; Newcomb PA; Peters U; Huyghe JR
    Cancer Med; 2023 Mar; 12(6):6583-6593. PubMed ID: 36341526
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Microsatellite instability in colorectal cancer: overview of its clinical significance and novel perspectives.
    Battaglin F; Naseem M; Lenz HJ; Salem ME
    Clin Adv Hematol Oncol; 2018 Nov; 16(11):735-745. PubMed ID: 30543589
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Analysis of DNA Damage Response Gene Alterations and Tumor Mutational Burden Across 17,486 Tubular Gastrointestinal Carcinomas: Implications for Therapy.
    Parikh AR; He Y; Hong TS; Corcoran RB; Clark JW; Ryan DP; Zou L; Ting DT; Catenacci DV; Chao J; Fakih M; Klempner SJ; Ross JS; Frampton GM; Miller VA; Ali SM; Schrock AB
    Oncologist; 2019 Oct; 24(10):1340-1347. PubMed ID: 31040255
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Sustained Disease Control in Immune Checkpoint Blockade Responders with Microsatellite Instability-high Colorectal Cancer after Treatment Termination.
    Simmons K; Thomas JV; Ludford K; Willis JA; Higbie VS; Raghav KPS; Johnson B; Dasari A; Kee BK; Parseghian CM; Lee MS; Le PH; Morelli MP; Shen JP; Bent A; Vilar E; Wolff RA; Kopetz S; Overman MJ; Morris VK
    Cancer Res Commun; 2023 Dec; 3(12):2510-2517. PubMed ID: 38085001
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Real-world application of tumor mutational burden-high (TMB-high) and microsatellite instability (MSI) confirms their utility as immunotherapy biomarkers.
    Palmeri M; Mehnert J; Silk AW; Jabbour SK; Ganesan S; Popli P; Riedlinger G; Stephenson R; de Meritens AB; Leiser A; Mayer T; Chan N; Spencer K; Girda E; Malhotra J; Chan T; Subbiah V; Groisberg R
    ESMO Open; 2022 Feb; 7(1):100336. PubMed ID: 34953399
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Advances in immunotyping of colorectal cancer.
    Wu Y; Zhuang J; Qu Z; Yang X; Han S
    Front Immunol; 2023; 14():1259461. PubMed ID: 37876934
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cytolytic activity correlates with the mutational burden and deregulated expression of immune checkpoints in colorectal cancer.
    Zaravinos A; Roufas C; Nagara M; de Lucas Moreno B; Oblovatskaya M; Efstathiades C; Dimopoulos C; Ayiomamitis GD
    J Exp Clin Cancer Res; 2019 Aug; 38(1):364. PubMed ID: 31429779
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Identifying and clinically validating biomarkers for immunotherapy in colorectal cancer.
    Yeh YS; Tsai HL; Chen PJ; Chen YC; Su WC; Chang TK; Huang CW; Wang JY
    Expert Rev Mol Diagn; 2023 Mar; 23(3):231-241. PubMed ID: 36908268
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The Potential Value of Immunotherapy in Colorectal Cancers: Review of the Evidence for Programmed Death-1 Inhibitor Therapy.
    Toh JWT; de Souza P; Lim SH; Singh P; Chua W; Ng W; Spring KJ
    Clin Colorectal Cancer; 2016 Dec; 15(4):285-291. PubMed ID: 27553906
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pan-Cancer Analysis of PARP1 Alterations as Biomarkers in the Prediction of Immunotherapeutic Effects and the Association of Its Expression Levels and Immunotherapy Signatures.
    Zhang X; Wang Y; A G; Qu C; Chen J
    Front Immunol; 2021; 12():721030. PubMed ID: 34531868
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Immune Microenvironment in Microsatellite-Instable Endometrial Cancers: Hereditary or Sporadic Origin Matters.
    Pakish JB; Zhang Q; Chen Z; Liang H; Chisholm GB; Yuan Y; Mok SC; Broaddus RR; Lu KH; Yates MS
    Clin Cancer Res; 2017 Aug; 23(15):4473-4481. PubMed ID: 28264871
    [No Abstract]   [Full Text] [Related]  

  • 40. Defining the current role of immune checkpoint inhibitors in the treatment of mismatch repair-deficient/microsatellite stability-high colorectal cancer and shedding light on future approaches.
    Tan E; Sahin IH
    Expert Rev Gastroenterol Hepatol; 2021 Jul; 15(7):735-742. PubMed ID: 33539189
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.